Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 18/20 | 1.00 |
| ▸ | HRH1 | P35367 | 7/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.69 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.69 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.69 |
| ▸ | HTR1D | P28221 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2324239 | 0.99 | DRD3 (0.98) | DRD3KCNH2HRH1DRD2CHRM2 | |
| SCHEMBL2307061 | 0.86 | DRD3 (1.00) | DRD3KCNH2HRH1DRD2 | |
| Hydrochloric Acid SCHEMBL2320905 | 0.85 | DRD3 (0.98) | DRD3KCNH2HRH1DRD2 | |
| SCHEMBL2307625 | 0.82 | DRD3 (1.00) | DRD3KCNH2HRH1 | |
| SCHEMBL2312933 | 0.82 | DRD3 (1.00) | DRD3KCNH2HRH1DRD2CHRM2 | |
| SCHEMBL2308829 | 0.82 | DRD3 (1.00) | DRD3KCNH2HRH1 | |
| SCHEMBL2287102 | 0.82 | DRD3 (1.00) | DRD3KCNH2HRH1DRD2CHRM2 | |
| Hydrochloric Acid SCHEMBL2313983 | 0.82 | DRD3 (0.98) | DRD3KCNH2HRH1 | |
| SCHEMBL2311853 | 0.82 | DRD3 (1.00) | DRD3KCNH2HRH1DRD2 | |
| SCHEMBL2316059 | 0.81 | DRD3 (1.00) | DRD3KCNH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751163-B1 | BENZAZEPINE COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2011-08-10 | — | — | EP | claimed |
| EP-1751163-B1 | BENZAZEPINE COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2011-08-10 | — | — | EP | disclosed |
| US-7989444-B2 | Compounds having affinity for dopamine D3 receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-7989444-B2 | Compounds having affinity for dopamine D3 receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-7989444-B2 | Compounds having affinity for dopamine D3 receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | DRD3, DRD2, SLC6A3 | DRD3 1/4885KCNH2 856/4885HRH1 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.